<SEC-DOCUMENT>0001144204-12-030933.txt : 20120521
<SEC-HEADER>0001144204-12-030933.hdr.sgml : 20120521
<ACCEPTANCE-DATETIME>20120521145310
ACCESSION NUMBER:		0001144204-12-030933
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20120518
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120521
DATE AS OF CHANGE:		20120521

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		12858540

	BUSINESS ADDRESS:	
		STREET 1:		9920 BELWARD CAMPUS DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		9920 BELWARD CAMPUS DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v314098_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, DC 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported) May 18, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVAVAX, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of Registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 32%; vertical-align: top; font-weight: bold; text-align: center">Delaware</TD>
    <TD STYLE="width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: top; font-weight: bold; text-align: center">0-26770</TD>
    <TD STYLE="width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: top; font-weight: bold; text-align: center">22-2816046</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">(State or other jurisdiction of incorporation or organization)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">(Commission File Number)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 48%; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9920 Belward Campus Drive </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rockville, Maryland</B></P></TD>
    <TD STYLE="width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 48%; vertical-align: bottom; font-weight: bold; text-align: center">20850</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 49%; vertical-align: top; font-weight: bold; text-align: center">Registrant&rsquo;s telephone number, including area code:</TD>
    <TD STYLE="width: 3%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 48%; vertical-align: bottom; font-weight: bold; text-align: center">(240) 268-2000</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>(Former name or former
address, if changed since last report.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01. Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 27, 2010, the Securities and Exchange
Commission (the &ldquo;Commission&rdquo;) declared effective the Registration Statement on Form S-3 (File No.&nbsp;333-165496)
of Novavax, Inc. (the &ldquo;Company&rdquo;) originally filed on March 16, 2010 with the Commission (the &ldquo;Registration Statement&rdquo;).
The Registration Statement permits the Company to issue, in one or more offerings, shares of common stock, preferred stock, warrants
or units at an aggregate initial offering price not to exceed $150,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 18, 2012, the Company agreed to sell,
directly to one or more affiliates of RA Capital Management, LLC, 10,000,000 shares of the Company&rsquo;s common stock, par value
$0.01 per share (the &ldquo;Shares&rdquo;), at a price equal to $1.22 per Share. The Company will not pay any underwriting discounts
or commissions on this transaction, so the proceeds to the Company, before expenses, will be approximately $12.2 million. The Company
estimates that total expenses of this offering will be approximately $100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the offering, the Company
is filing as exhibits to this Current Report on Form 8-K the following documents:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; width: 0.25in">&bull;</TD>
    <TD>as Exhibits 5.1 and 23.1, the legal opinion and consent of Ropes &amp; Gray LLP relating to the Shares to be issued and sold in the offerings;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold">&bull;</TD>
    <TD>as Exhibit&nbsp;99.1, a press release announcing the offering.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company&rsquo;s press release announcing
the offerings is filed as Exhibit&nbsp;99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;Exhibits</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 12%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 85%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; font-weight: bold">Exhibit No.</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; font-weight: bold">Description</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">5.1</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Opinion of Ropes &amp; Gray LLP.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">23.1</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Consent of Ropes &amp; Gray LLP (contained in Exhibit&nbsp;5.1 above).</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">99.1</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Press Release of the Company dated May 21, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 29%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">May 21, 2012&nbsp;</TD>
    <TD COLSPAN="3">Novavax, Inc.<BR> &nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid">/s/ John A. Herrmann III, J.D.</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Name:&nbsp;&nbsp;</TD>
    <TD COLSPAN="2">John A. Herrmann III, J.D.</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title:&nbsp;&nbsp;</TD>
    <TD COLSPAN="2">Vice President, General Counsel &amp; Corporate Secretary</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;Index</B></P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 12%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 85%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">Exhibit</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; font-weight: bold">Number</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; font-weight: bold">Description</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">5.1</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Opinion of Ropes &amp; Gray LLP.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">23.1</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Consent of Ropes &amp; Gray LLP (contained in Exhibit&nbsp;5.1 above).</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">99.1</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Press Release of the Company dated May 21, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>v314098_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May 18, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 350.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novavax, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9920 Belward Campus Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rockville, Maryland 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">Re:</TD><TD>Registration Statement on Form S-3 (File No. 333-165496)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This opinion letter is furnished to you
in connection with the above-referenced registration statement (the &ldquo;Registration Statement&rdquo;), the base prospectus
dated April 27, 2010 (the &ldquo;Base Prospectus&rdquo;) and the prospectus supplement dated May 18, 2012 (together with the Base
Prospectus, the &ldquo;Prospectus&rdquo;). The Prospectus relates to the offering by Novavax, Inc., a Delaware corporation (the
&ldquo;Company&rdquo;) of 10,000,000 shares of the Company&rsquo;s common stock, par value $0.01 per share (the &ldquo;Shares&rdquo;),
which Shares are covered by the Registration Statement. We understand that the Shares have been offered and sold in the manner
described in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have acted as counsel for the Company
in connection with the issuance of the Shares. For purposes of this opinion, we have examined and relied upon such documents, records,
certificates and other instruments as we have deemed necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The opinions expressed below are limited
to the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based upon and subject to the foregoing,
we are of the opinion that the Shares, are duly authorized, validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We hereby consent to your filing this opinion
as an exhibit to the Registration Statement and to the use of our name in the prospectus supplement under the caption &ldquo;Validity
of Securities.&rdquo; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required
under Sections&nbsp;7 of the Act or the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>/s/ Ropes &amp; Gray LLP</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Ropes &amp; Gray LLP</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v314098_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Contact:</TD><TD>Frederick W. Driscoll</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"></TD><TD>VP, Chief Financial Officer and Treasurer</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"></TD><TD>Novavax, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"></TD><TD>240-268-2000</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVAVAX, INC. ANNOUNCES $12 MILLION EQUITY
OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">Rockville, MD (May 21, 2012)&ndash;/GlobeNewswire,
Inc./-Novavax, Inc. (Nasdaq: NVAX) </FONT>announced today that on Friday May 18, 2012, it sold 10,000,000 shares of its common
stock to RA Capital Healthcare Fund, LP at a price of $1.22 per share. The shares were offered under an effective shelf registration
statement previously filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novavax received proceeds, after deducting offering expenses,
of approximately $12.1 million. The net proceeds of the financing will be used for general corporate purposes, including working
capital, product development and capital expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The securities were offered by means of a prospectus supplement
and accompanying prospectus, forming a part of the company&rsquo;s previously filed effective registration statement, copies of
which may be obtained, when available, at the SEC&rsquo;s website at <U>http://www.sec.gov</U> or at the company&rsquo;s website
at <U>http://www.novavax.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release does not and shall not constitute an offer
to sell or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any
such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Novavax </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical
company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle
(VLP) and recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces potent
vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond
to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine
solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals
of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach
to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company&rsquo;s
website, <U>www.novavax.com</U>.</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Statements herein relating to the future of Novavax and its
financial position are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous
risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements.
These risks and uncertainties include those identified under the heading &ldquo;Risk Factors&rdquo; in the Novavax Annual Report
on Form 10-K for the year ended December 31, 2011, and filed with the Securities and Exchange Commission. We caution investors
not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read
our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking
statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise
any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration to these risks and uncertainties.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>###</I></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``M`2(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#\P?\`AMS]
MMG_H]/\`;$_\2D^/7_S?U]A?L&?\%8_VD_V8_P!I[X??$CXT_'WX^?&7X)W=
MQ)X/^,'@OXE?%?XD?%.R@\!>([BS34?&/A70O&.O^([>T\:>!+RTT_Q7I5SI
M%G;ZSKECI>K>"DO;:Q\5WLJ?DS>2&*VN9EQNBMY9%SG`9$=AD#&02H''/TXK
M[1_;A_9`\4?L=?%/PMX:U!-0U#X??%KX7^!_C3\'?%5]'$&UWP?XUT&PU'5=
M"NY[;_16\1?#WQ-/J7A77(E\BZN=.M_#OBV?3M+LO&&F6B_Z$YIE'"^+2R#'
M9?E\9YW@\PC0IQPE"G5JTL+3I+%_5ZL:?N8BA2Q,<3!IJ<(T:E>#_=29_"F6
M9MQ-AF\[PF8YA4IY/C,!.O.IBJ]6E2J8BI.6$]O2<VY8>O4PSP\[KD<JE.E.
MWMHM_P"G'HFM:1XET;2O$/A_5M-U[0M>TO3]9T36](O+?4=*U?2-6LH-0TS5
M=,O[226UO=/U*QN;>]LKNWDDAN;6>&>)WC=#7\J7_!RE\=?CG\'/'O[&MO\`
M!SXW_&?X/VWB3P?\?KCQ%;_"?XK_`!`^&L'B&XTG6O@U'I4^O0^"/$6AQZS-
MI<6HZA'ILNHK<R6$=_>):M"MU<"3M/\`@W0_X*`CQ]\/M2_80^*.O%_&7PBT
M>]\5?`+4M3NW>?Q'\(5O$.O?#RWDN-[W&I?"?5-0ANM`LA<M*?AQK=MI>C:9
M;:'\--1G3YY_X.F/^2A_L-_]B5^T?_Z?/@;7\P<$\+UN'?%[!</9I1IXF&&E
MFJI3K4H5*..P<LFQU;!XV-.:E'][!0FU:]*O&I2O>$D?T3QAQ+2SWPMQ.?97
M6JX6=>&6<\:-5TZ^#Q*S7`4L7A9RIR4E*G-RB^E2G*G4]Z,TWVO_``;<?'KX
M\_&/XP_M56'QB^.OQK^+^GZ#\-/A;>:!8_%?XM?$'XDV>A7E]XM\70W]YHUK
MXT\1:Y!I5W>P6MM!>7&GI;S7<-O!%<.\<,:+_2+^UU^UK\'?V*?@AXE^/'QM
MUJZT_P`+Z#):Z;I.B:/!;W_BWQYXNU1;DZ#X$\$Z3<7-G%JGB;7#9WDT:W%W
M9:9I.D:?K'B77]1TKPUH6M:M8?RQ_P#!KE_R6K]K_P#[)5\)/?\`YG#QM7BW
M_!R7^T-K?Q"_;*\&?L]0:E-_PA7[._PTTC4[C2%=4@F^)_Q;B'B76]7ND0JM
MT]IX`@^'NGZ,]RK3:8+OQ']D:.+7;U9/:XAX.PW%'C1CLBA".#RVEALOQV/C
MA(0H\N!P^59;[6%%*+A"KB:]:E0]HXOV<J_MN2IR>SEYF1\5U^'/"3!YS*<L
M7F-3$XW"8.6*J3JJ6*Q&:8R-.5:4FY2IX>C3JU_9IKVBHJBI4U+VD/FC]K?_
M`(+F_MX?M-Z[JMOX,^(6H_LO?"V6=QHG@'X':O=:%XL2P6:1[.;Q;\9[:+3O
M'VM:Z(9#!?3^$KGX?^%KJ-8E7PC%<1R7=Q^;FA>%_P!I;]I?5-1G\,>&?VA?
MVD-<L[C;K%SX=T#XI?&_5K2YD!N<:O=Z;9>*[^VG8'SQ]NFCG8L\P.)97?Z.
M_P""9'[(6F_MP_MH_"CX#^*)=0M_AT\6N_$#XLS:5/-::F_PW\"6*W^JZ19W
MEM-;W>G/XPUVZ\.>!)-8L[B"_P!#A\4OK.GR&_L+:*3_`$F/A]\._`GPJ\%^
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M!_QGDM[WQO9Z\$A40?\`"=S?$/PVT7VBUCT'3[J\&LV7]\WQ,^%WP[^,O@7Q
M%\,OBMX+\-_$+X?>++%].\1^#_%VDVNMZ#JMHS"15GL+Q'C2YMIUCN["_@\J
M_P!-OX+?4-/N;:^MH+B/_-5_X*,?LH6W[%'[97QE_9\T:[U&_P#!6@:GI/B;
MX9ZCJTIN-4NOAOXYT2R\4>&K34+MR9+_`%'PN=0OO`^IZK,L<VLZEX7N]9,4
M2Z@L:OA'C#AGQ6EC<EXAX8P,<PI85XE>U<,4L1A8SI4*E3"8SV%#%8'$T)UZ
M=HTYRGRS=:G5Y85:<#BGA3B#PR6"S?(N(L=4P%7$+#3Y>:@Z%?DG6IT\3A%6
MGA<7AZ\:51MRA%1<%2=-2E&K/_12_9C_`&F_@Q^VM\"?#GQK^#&O7>M^!/&E
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M_'#XH^/?BCXX\/RZ)\;OAQXA^)WC;Q3\0?%]WX,U3^R_`GQ#T"+Q#XNU75]4
MC\/^#O$,/@'5-/TY[YH8K_XB:M):Q1IYBC^I4'-?YD/_``34_:9'[(G[<?[/
M?QJU#4!IO@RS\90^"/BA-+<-;V*_"[XE+_PAOB[4-4\ME-Q8^$8=4LOB$ELV
M]7U+P=IL@5FA53_IMC<!AAM(8@C.<$$]\#()'!P,@CC-?&>-7#E/(^+?KN%H
M0H8#/<+#&4J=*$*=*GB\-&GAL=2A"G&*N[8?%3=KN>+DVYM\Q]7X0\0U,YX8
M>%Q5:5;&9-B)X2K.I.4ZL\+57ML%4J.5Y>[!U<-%RDW*&%B[+5'Y:_\`!9/]
MJZ]_9'_8(^+WBWPOKEYX?^*'Q*BL?@C\)=4TR[N=.UC3?&/Q'BU"UU/Q%H6I
MV4D5UI>N^"/`&G^-?'6B:C"Z-;:UX;TU5=9)HS7\+_PK_:/_`."A7QK^)WPX
M^#7P\_;(_;"OO'7Q6\:>&?AYX1@E_:B^/CVD>N>*]5MM'LK[4W3QZS6^C:4;
MEM6UV_DQ!I^CV-]?7#I#;NP_67_@Y0_:?;XE?M5?#S]F/0;_`,SPS^S;X+77
MO%UO#*RQS?%OXN6FG:TUG?6^XQ7#^%_AG:^"KG2KK"S6\GC[Q/9%%"EY.B_X
M-K/V2F^(7[0'Q'_:]\3:9YOA?]G[2I/A]\-[B>!C!>_&#XBZ/(GB74;"Z#;$
MO/`/PMO9]/U"TE!\R/XO:+>Q,)+#(_2^#<%EO`_A3B^*,SP6$Q689C0JYOAX
M8S#TJLW+%1I8+(L)!U(N3I5VZ&,E&+2C2QE:I:U.<E\!Q7C,QXQ\3,-PWEN.
MQ>'P."K4LMQ+PN)JTHQAAD\5G&*DZ4X6G1]["0D]/;T:,-Y-']EGPQ\%1_#3
MX;>`?AW%XB\4^,D\">#O#?A`>+?'&NZEXG\:^*V\.Z3::5)XE\6^(]:NKS5M
M<\2Z[):OJVMZIJ-W<7E[J5U<SS2N[DU_-C_P<0?\%#O&7P:L/AC^R1\`OB-X
MM^'GQ+\5I8_%OXM^,_AUXJUSP=XP\+^`M-OKVR\`^#K'Q1X9O=-UK2+CQYXD
ML=4\0ZW'IVJ66H1^'?!>GZ?J$$^A>.F2Y_HX^,WQ=\"_`3X3?$7XT?$O5AHG
M@/X7>#]<\;^*K\!'NAI.@64MY-9Z9;R30?;]<U1HXM*T'2H95N=6UJ^T_3+-
M9+F[AC;_`"]/VC_CWX\_:H^//Q5_:&^(:3S>-?B]XQN_$L^B6+SZJ-#L9$MM
M(\(>`M"VI]JU&Q\'>%[#0?!>@JL7VS4+;2+1WC:\NFW_`)_X-<)_ZQ\15\]S
M*C&OEN2-8B2KTXRHXO-L4^;"TZD))TYPH0]KC*L&I)3^J\RY)W/MO%OBB609
M%1R;+JLJ.89PG0BZ4VJV$RV@N3$UH33YXSJ3=+"TI74FI8B2?-3L=G_PV]^V
MSDK_`,-I_MAY&,X_:F^/)P3G`P/B!W`)_F!7]:?_``;P_M_>+/V@?A[\2?V6
M_CA\0/$_C_XQ?"6>[^(_@3Q=X\\2:QXM\:>-?@[XIU>&'7K/5_$GB"ZU37M>
MOOACX^U:.R;4=9U6:2W\+_$#P-X>TV(V/AN<P?*_[9G_``1^3X1?\$8OA5J&
ME^'X#^TE^S$=8_:0^--Q8PQSWNLP?%'3]#;]HOPN]U!<26=WI_PL\,Z%X&N+
M+6XHX_MWA?X`QRPVT%QKMU&W\YG['O[3GBS]CG]I7X1?M(^#HKO4;GX<>*(K
MKQ#X=LYXX'\:?#_5H)M$^(/@HM<'[&)_$GA.]U.ST>[ODFM]'\1QZ%XA6%KK
M1[5D_8,PP?#?BGP?GU#A_!X.CC<!F.,P^7UJ=*A2J/'9;453`UU4ITZ<EA,X
MP<XT[R2A&.*JMN<\*U+\JP.+XA\-^*\BJY]C<97P6.P.%KXRG5KUZM)87'4X
M4\92<)SE%8G*\5>6B<YK#P248XAN/^FI\>?AE??&;X,_%'X5Z5XU\5?#?6/'
MW@?Q#X9T/XA^!_$.N^%?%W@3Q!J.FW$7A_QAX>UWPWJ.DZS8ZEX;ULV.LPBT
MU"V2\6SDT^\,MC=7$,G^:OXP_:L_X*!_#GQCXN^'?CK]K[]L?0O'/P^\5^(_
M`OC/1)/VIOCO(^D>+/!^M7WAWQ'IID7X@-'.EEK&FWMO'<1EH;F.-9X6>)U8
M_P"FKX"\<>%/B=X&\(_$?P'K=KXE\$>/_"V@>-/!WB&QW_8]<\,>*=(M-<T'
M5[42QQ2+!J.E7]I>1)+''+&LP26-)%91_$1_P<:_LF-\'?VL_#7[2OAG2Q;^
M!OVH-`_XJ22TMQ'9Z=\:OAUIVF:-XB-QY44=K9MXT\$2>#]>L(F9KO6-<T7X
MA:O,TLJW4M?E7@;FF#HY]CN&LUP>&J?VK2EB,''&8>$ZM',<!"3K89*I";@Z
M^%=2<X>[%5L'"+:E4FJGZ9XQY=C:V28+B'*L7BZ+RZHJ>,>#Q%6G"K@,9*FJ
M6(DJ4U&?L,1&E"$TK^RQ4Y2;C3AR?NU_P0&_:]\1_M/?L87GA3XE^,_$'CGX
MP_L_>/\`6?`_BKQ+XS\0ZKXI\:^*?"'BB6X\;?#GQ3X@US6[F^U75&^PZGKW
M@&UOK^\N;VZ3X<S37,LLG[Z;]S*_@"_X-]?VF3\!_P!OK1OAMK.HBR\#_M1^
M$[[X4ZG'<7!M]/C^(FAK=>,?A-JEP%5O.OIM0LO$_P`/]'A93NO_`(E*`\>?
MG_OZ#;P,=6&!W!)P,=N,D`YP#T]:^3\6>'8<.<:9C"C35'`YLHYQ@8148TX1
MQ?-];I4TO=C&CCJ>*48)+EI>S?*HRBW]+X7Y]+/^$,!4K59UL;ESEE>,G4DY
MU)SPL(?5ZDY2UE*K@YX><I/>I[17;C)G\]G_``</_MH>+_V<OV;OAG\'?A)X
M\\5?#SXM_'[QY]MD\4>!/$FL^$?&/A[X6?"R32O$'BB[T;Q3X:U#3M>\.WFO
M>,=2\`>&S-:7=H=:\.7/C+23+);&^A/\W/\`P3W\;?MR?MG?MB?!#]GYOVRO
MVSI?"?B'Q*GB3XJWEI^U)\?8FTSX0>"@OB+X@R&[@\?2/IEWKVCVG_"%Z!J?
ME31V?BWQ5X>,T3K+L:I_P6J_:>/[4'_!0KXP7^E:B+_P+\$)(OV=_`7D2+):
MR6WPUU#5$\=:K$8R;:X;5_BKJOC<VVJ0,ZZGX;L?#!\V2&TMQ'^[W_!L]^R9
M_P`(=\'?BG^V3XHTT1Z_\:-8N/A9\++BYMU\ZV^%/P]U9U\9:OIUPK+(MMXU
M^*5G-I&HVTT9#+\)='O;>39>/N_8\/A<!X>>$,<;BL%@I9[FF']M1GB,+0JX
MA9IGE-/"0YIQG+FRW+80Q$J<FJ:G@:L90YZDE/\`*JN+Q_'7BH\'A<;C89+E
MF(]C6A0Q%6EAY8#*)1^M3DJ<HQ:Q^/;H1FDZDJ>*HRYO9TH^S_J%7`0L0JJ1
MG:HP`H7CC)P<=>3C`&3C)_C1_P""_O\`P4E^)]G^T=X8_99_9N^,7Q(^%NG?
M`S2TUGXP^)?A)\0O%GP_UCQ%\4O&FFV5[IG@C4-<\%ZMHVH7ND?#[P7+I^HW
M-DM_/I\_BCQSJ%EJ5G%K'@R`P?U!?MO?M4>%_P!BW]E_XN?M&>)EM+Z7P%X:
MD_X1'PW=3M;CQE\1-=F30_A]X01XW6X6'7O%E]IEMJMS:K--I6@)J^N/$UMI
M5PR?YH/A[0OBU^U'\<]*\/V5U<>._CG^T1\5XK0ZKJ1,;^)/B7\4O%32:AK^
MLRP*4T_3Y]>UJZUK6[J-([/1M)CO+K;!967[OXKP1X2P^/Q^.XJS6E2EE61T
MZM'#?6E&=">.JX=RQ.(G[7FC*EE^`JRG-U$XQEBJ52+<J6GUWC!Q+6P.!P/#
M.5U:L,SS>I2J598:2A7A@Z5:"HTH.'(XU,=C(1I147'FC0K1=E)7]&;]MS]M
MF1&7_AM+]L,JP*-C]J7X\].589'Q`!R,LI*G((/(8<?W=?\`!%_]MB;]M#]B
MSPC?^,-;GUKXV_!:>/X1?&:YU"Z>YUC7-5T'3[63P?\`$74)KF>6^O[CXC^#
M9-*UO7-9FCBMKSQ];^.[*S#QZ2QK\*?^"ZO_``3.\'?LT_LY_LA_%WX*:7)+
MX8^!W@KPU^RO\6+^"PC@N]=LG;4/$/@'XL>(8+&-;.WU77O'^H^/K/QGK$TS
MRZGXC^(O@^P@5(+-0?SX_P"")G[:!_8^_;:\*6/BC63IGP;_`&BQI7P7^*!N
M[D6^DZ/JVIZH3\*/B!?-)/;6<'_"'^,K]]%U'5=2E6PT'P/X\\>:K*NZ)'3[
M_B?+LE\2_#JIGW#F7X?#X[+:N,QF&I4*%&EBI/`5)0QF!K2IQ@Y/%9?%8VC1
M<4U5>$BKRE.9\/P[F.=>'W'E+)>(,=7Q6!S"CA<+7JUJ]:K1C]?IPG@L92]I
M.:A'#8U5,)4J*W-3^LRVC&*_J#_X+.?LB_M5?%'X9_\`#0O[%_QR_:0\#?%W
MX4Z',OB[X._"#XW?%?P3HOQB^'>G-<:E>3^'_!?@_P`5Z1I$_P`7/"2R7M[H
MCZ?8C5_B#H'VOP?.FM>(;/P%:V7\6/AW]OS]N;P_K.@^*=$_;3_:KN=2T#5]
M)\1:0NO_`+0WQ=\6^'[B^TB_@U'3TUOPMXD\9:GX<\3Z)/<6T::IX>U_3=1T
M36[$W.F:M8W=C<7%N_\`J)Y5\C+`C<,@LC`@[6P00RLK#KP01D>M?QA_\%Z?
M^"4@^%NL^)?V[?V=/#JQ_#?Q/JDNI_M(?#[1;(1Q?#WQ3JMVHD^,^@V5N/+7
MP5XNU"X"?$NUABB/A3Q7/%XU)N_#_B;Q+<>"_B_!_C+*W*GP=Q)@\OK4L3)T
M\DQN+PF&J6J5U[V5XJI.DY3IXAN^!E4FXJK4EA7[M6@J?U_BKPKFL83XIX?Q
MF/HSP\>;-\%AL7B*<90I--9AAZ-.HHPJ4K6QL:<8MTH+$*TZ=9U/Z0_^"<'[
M>'@C_@H%^S;X=^+VAKI^A?$+2&C\*_&OX=6LSL_@#XCV-I%+?VUDES++=W/@
M_P`36S1^*/`>K22W#7GAS4(M/U&>'Q-HOB/2],_$S_@OI_P5/\3_``TO[7]B
M?]F/XA>(O!GQ$B?1/$W[0/Q+\`Z_J7ACQ7X'T]H[+Q!X/^%'AGQ5H-Y9Z[H?
MB;Q$ATWQ;X[U#2+_`$J[T[P=+X=\,I/?P>,_$UIIO\V?[$7[=/QT_8%^)_B/
MXG?`[4-->X\7^!]<\$>*_"7B2":^\(^)([BQOI?!NMZOID$T/VC5OA[XKGMO
M$WAZZAD@O6MCXB\+K?6>B>-/$2W/F_P7^#GQX_;:_:(T3X9>!%U+XE?&[XT^
M+=9US7?%'B>^NIE:^U6^FUWQY\4_B-KZ07<]EH.FRWE[XA\7:WY%S=SW$\>G
M:+IVJ:_JNC:+>_8Y5X095P_Q;F'$.9UL+_JIEL)9CE6'Q<HSC0K/VE2=/,(U
M%*+PN3PI2G1G54OK/-A:TVG1Q-&I\GF?BMF>><+9?D>74\2N)<QJK+\PKX6,
MHSKTTX4Z4L"Z7)RXC-)5(0J*+3PTEB817+4H5Z7Z&_\`!.W1/^"D?_!0GX_Z
M=\*?"'[:O[:7A[X>>&UT_P`2?'#XHP?M.?'*:U^'?@66ZEC6"Q^U>/9+*[\?
M>,I+.^T7P!H,L5TUU?0:IXBO+&X\,>$O$TMI_H&^"/"6F>`O"'AKP7HUUKU]
MI7A;0]+T&PO_`!5XFU_QIXHO[72K*"QAOO$GB_Q5J&K>)O%.O7B0"XU?Q!K^
MJ:AK&L7\EQ?ZC>7%U<2R-\O?L+?L4?"K]@SX`>&_@;\,%;59X91XA^(7Q`U#
M3X=/\1_$[XAW]E;6NO>,]>@AFN1:":*TMM)\.:$+N\M_"OA73M&\.6UW>KIS
MW]W]E5^&^(?&%#BS.&\MP=#`9'@)3HY;2I8:GAZV*B[*>/Q?+%5'5KM?NJ4W
M;#4.6"C[6=>I5_9N`^%:_#.56S'%U\=G&,4*F/JU<15KTL/9<U/!853E*$:5
M#FM4J12E7J\T^;V4:,*91117Y^?<G^1EJ'_'C??]>DW_`*+DK_01_;K_`&![
M;]O+_@F1\'O#_A;3+27X^?"?X*?#KXB_`;4W:VMI[[Q+;?#;PY'KWPXNKV=H
M1'HOQ1T6T70'6XN[?3;'Q9:>"_$^HM+%X8CB;_/NU#_CQOO^O2;_`-%R5_JQ
M_LX`G]G7X!8S_P`D3^%/0X/_`"(>@=#V/<'J",CFOZQ\<\SQN35>",VRZJZ.
M-R_,\SQ6'J;QYZ=/+[PJ1VG2JP<J56F])TYRB]&S^7_!C+L+FT.,<LQU/VN$
MQN`P&'KPV;C4GBTI1?V:E.7+4I3WIU(0J)IQ37^7E\'OBW\2/V=OB[X!^-'P
MSU"Z\*_$[X3>+K/Q-H$FHVUY:M:ZOI$T]EJGASQ-IA>SOGTC6;&75?"?C/P]
M-);3WVB:EK6B7+P&YE9?W2_X+O?M.^`OVR?AS_P3/_:-^''F6WA_XA?##]HZ
M>_T*YN%N=2\&>+M,\1_!+3/&7@769DB@2;5O"'B&UOM&N;J."&WU2&"TUO3U
M?2M5T^::]_P<+?L`_P#"@_CK9_M?_#C2O)^%'[2?B"Z@^(UG91(MIX-_:!:T
MN=5U+4)8XHH4M-,^,FEV&H^+8W`N<^/=%\?7&HW<+>)/#UG7\\LFL:O/HVF>
M'9M2OY=`TC5M>U_2]%DN9'TO3M;\46/AK3/$>K65FS&&WO\`7=/\&>$;+5+B
M-%DO+;PWH\<Q<6,1'WN44\GXWGPAQ_@>6AC,!2QL:M.ZG-0Q>!Q>!QN55I15
MW+`XZK[;#U)NSA"K)1:QKJ+XG-)9IP=#BG@G&<U;"8V>#G2FUR0G4PN-PF)P
MN9TXR_Y=XO!4IPK1AJJRHTF_]C<(_P!/7_!KG_R6G]K_`/[)7\(^AQ_S./C6
MOS\_X+W^'=3T'_@J?^T'J&I0RPV_C3PW\#_%FALZD+<:-#\&/!'@AY[?(Y@'
MB#P7K]KN7*?:+:X3.]7`_03_`(-<?^2U_M??]DK^$?\`ZF/C:ON3_@X3_P""
M=WC']HCP+X-_:Q^"7AK4/%OQ/^!GAO4?"WQ'\&:':37_`(B\9?!=]0U#Q+;:
MIX<L(3)<:OKGPNUZ]U_5D\-V-N^H:WX;\8>*+JQ%WJN@Z5I.I_G-7/L%D/CS
MFL\?5IT,-FF68/)WB*S4:="MB<NR7$X:4YO2$:N(P=+#<SLHNNI-I)W_`$.&
M28K.O!/+HX.$ZV(R[,<9FD:%.,IU*M+#8_,Z.)C3A!.=2<,-BJM=4XJ3E["R
M5]5^-7_!N9XRT3PM_P`%)H='U:>*&^^)?[./QA\`^%1(5#W/B*TUSX;?%"6U
MMPV"TQ\*?#3Q3=D1Y<06DKA2B2,G]\JX`QGOQR.<\CZ\$=.]?Y-/PX^(WC'X
M6>.O!7Q5^&/B>\\*^._`/B#2?&'@GQ7HS6\USH^N:/=1WFGWT45S%=6&H6KL
MAMK_`$S4;:\TC6--N+S2M6LKW3;V[M)OZ\O@!_P<\?":Y\)Z=9?M3?L]?$KP
M]X]M+6"+4=?^`2>%O&'@/7[N--MUJEMX>\=>-/!WB;P3'>2DR0Z`=6\?K8`K
M')XFN\>8./QD\/>(,ZSK#<0Y%@IYI2J8&E@L9A:$X?6\/6P\ZDH5:="<XSKT
M*U*I"-L/&I4IU:<I5(1A-3.CPFX\R+*<GJY#G.,AEM6GC*V*PF(Q$)QPN(I8
ME4U.C*M&,HTJ]*K3J2_?\D*E.I34)N4)1/ZI21T)`R._^17^?G_P<*>--%\7
M_P#!3;QOINCS1RS_``X^#WP<^'WB+R_^6?B$Z3K'Q$>&0X`,T&A?$308YE^]
M%(&ADVRQ/&GZM_M%_P#!SQ\-4\(ZEIW[)G[/OQ%U/Q_?6=Q:Z;XK^/Z^$_#/
M@SPU>NC+;ZU_PB7@+QGXT\0>-EM2=W]A76N_#U;A]KG6#`K1S?R(>.O'/BGX
MA>+_`!;\2/B%XBOO$WC3QMXCUKQAXR\5:S)#]MUSQ'X@U";4M9U6[\B.WLX'
MN[ZYDD2TLK>TL+1&CL]/M+6TBM[:/3P:\/>(,CSG%\09]@IY7".`JX#`X6O.
MG]:KUL54H5*M>=&G4G*C1I4J,Z*CB%3J5*U>,J<)0IN3S\6N.\BSC*<-D>2X
MR&85)8ZEBL7B*,*BP]"E1IUHTZ<*M2G"-6I5J5(N4J+G"G2A+GG><4?L7_P;
MW^&M2U[_`(*>_#34=.B>6V\$?"OXU^+]==%++;Z/-X37P+'/*P.(XVUWQQH=
MODY!EGA4`%@:_N?_`&F_@%X2_:D^`'Q=_9[\<`1^'/BUX'UKPA<Z@+:.ZN/#
M^HWEL9_#GBW3X97CC?5_!OB:#1_%>BAW$:ZKHUDSY56Q^)?_``;^_P#!.SQG
M^RY\+?&/[2WQO\,W7A3XQ_'W2](TCPIX+UVSFLO$_P`.O@MIMRVL6T7B"SN(
MX[C1/%'Q,U[[#XCUOPU=JU]H?A_PUX"@U:+2?%#^(]$T[^BHCVZX'O@GFOS3
MQ9XFHYOQW/'9/B;PR.E@<#A,;1:L\7E]6IC:E6A4BUSK#8_$3I4JMWS_`%>-
M2-E*'+^B>&'#];*^"Z6#S2ARSS:IBL=B,)6BTXX?&TZ>'ITJT7UK82C3J3AH
MX*KR2]Z+;_R8?B!X!\4?#7QGXZ^%?Q!TI=,\:?#WQ7XI^'OC;1]YEAM/$OA+
M5K_PWXCLH)F"+<VB:GI]Y%:W2@17EMY5RG[J5,?Z&G_!-;]N3PQ\4/\`@EMX
M'_:5^*7B(K-^SY\+/%'A?X_ZLTS7NJV^J_L]:++%XAU_41),OG:WXT\#:5H'
MQ"2U$R&23QA:P`1O)Y2?SK?\'('[)I^$W[4OA#]J3PSICP>#?VF=!CTCQG/$
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MRKINGZ;80IE(HJ_TC/\`@FE^R7#^Q7^QC\%?@=>6]M%XYL_#Q\8?%VZMVBG%
M]\6_'+KXA\<Q&_B'_$QM/#>H747@G0;UMK2>%O"^A1M'%Y*Q1_Q;_P#!##]D
MK_AJ+]O+P/KFO:8;WX9_LT6UM\=_&3SP226-YXET+4([7X0>&99E62%+N_\`
MB`MIXO\`LETC6^K^'?A]XJT]B#*2/[T?VBOCKX"_9G^!_P`4/CY\3;I[;P3\
M+?!VK>+-:6!H!J&J-9Q"'2O#FCI<2Q1W/B#Q7KESIGACP[9-(OV[7M7TZS#*
MTX8?!^.6<.MB\@X$RBFW'"1PF(JX.@E[V*KP6"R?!1I02:G2PTJE2G3M)3CC
M<*XVE3U^U\&LI]CALZXTS6K%3Q3K4(8JLFG'"TI?6LTQLJDVDH5L1&"G+[/U
M2NI2<9Z?S$_\'*W[;>RV\"?L$^!-67S+YM%^,/[0CV,ZD?V7:W4L_P`(_AOJ
M)CFEC8WVLV<WQ2U[3+F"VOK/_A'_`(6ZG!)+I^LW,4OX,?\`!,/5_P!EWP?^
MV9\+?BA^U_\`$C3OAY\(/@W/-\5+5;[PIXY\8MXS^)/A>YLV^&WAR/3?`7AG
MQ-J5K!I7BBYM/B!?7^I6D6DW$'@E?#]P\QUU43Y.^.WQL\;?M`_%SXH_M`?%
M.]2Y\<?%+Q9K'CCQ5)%/--8Z6UX0MCX=TF2ZDDGC\.>#]!M=-\*^&;>:61K'
MPYH>E61D86X:OWB^&?\`P;6?M;>/_AUX$\=:S\:_@_\`#;5O&7A#P[XIU+X>
M^*?#?CVY\3^";KQ!I-IJS^%O$<ME9Q68\0:$EY'INNPVAFM;75[:]M;>ZNH8
M4F?]*H8'AS@#@3!\-9YG2R.6;X/%4<5F&':>)Q.88FC!9I6P[CA,;:="G7IX
M:AB)X5^RHQP_+-3A&3_/*V/XBXYXSQ/$.39*\XCE.)PU7"8*NU'#T,#AZTO[
M.ABHRQ6&DU5G3GB*M&&(4*E>55SBZ;E3/Z%M3_X+C?\`!)76].U#2-9_:>TG
M5M(U:QO=,U32]2^!?[0MYI^IZ;J-O+:7^GW]I<_!^6"YL[ZUFFMKNWFCDBF@
MEDCE21&93_`E\>/#?PH\(_&GXI>&_@/XX3XC_!/2_&NKCX2^-5T_Q/I4VL?#
MV_F74O"T&IV/C+1O#_B2+7M`TF^MO#7B.;4M(L_MVOZ/J6H6(N=+N["]N?Z#
MO^(7[]J,]?VH/@`>G7PG\1^W_;#_`#VQ7RC^VG_P0H_:2_8L_9^\4?M%:Y\4
MOAC\5O"W@C4_#D/B[1?`VD>+--US1=`\0ZO;^'U\4XUR#R+[3M*UO4M%M]5M
M[=A<6>G7]QK4Q73])O2/`X`J^&/"N8U</P]QGB\97SR6$P:P&.E*5&MBE5Y<
M'*FUDN!Y,0Y5IT:<I5E"2J^SDFU!P]OC>EXC\38"E7S[A'"X2CDT<1C'C<'&
M$:M##>SA+%1J*>;XOGP_+2A5FHT7.,Z:DOM)_L-_P;9_MIOXY^$WCC]B+QKJ
MK3^*?@F+[XC_``?:ZE$EUJ7P=\3ZY$GBOP[;C9YTW_"M_B+K4=T+BYN6":#\
M2O#NAZ;;0Z?X8?;^K_\`P5H_9&E_;-_8;^+?PRT+2_[4^)OA.TC^+WP:BBB,
ME[/\3OAY:7]]I^AV"AT07?CSPU=>)_AJLTH=+6/QD]WM#V\;I_GS_LF_M)>+
MOV0_VC?A)^T?X*BDO]5^%_BJ+5]2T&.6*%/%_@W4K6YT+QYX+EDG#VT9\6>#
M=3UO1+*\N$FBTG5+S3]<BC-WI=LZ?Z@WPY^(7A+XN?#[P3\4/A]K,'B#P1\1
M?"6A>./!FOVV^./5?#7BG2K76="U%8I(XY[=[C3[VVDE@GACGM9O,M[B*.>)
MT'YUXM9'B>#>-L!Q;E,?8T<SQ<,UHM)QIT,ZP=:G5QM"=DERXNU/&.#_`(BQ
M.+I1M"C4Y?OO#+.</Q=P?CN%\SDJE?`8:>65E*:=2ME.*I2I8:O!WWPW[S"P
ME%<T/88:;]ZK!R_RB_"'B[Q%X+\0^$OB#X(U231O&/@OQ%X<\=>#-:C1EET?
MQ3X5U6R\2>&-56-OF$FFZUIUA>B)QO#P&-AN#5_HV_'W_@H=X8\)?\$M=<_;
M^\%SVUE<>+_@3X>\3?#'3)I+6_;3_BY\3[73?"O@_P`+:A"S&.^G\&_$S7X+
M#Q?:K$Y@L_#/B&::$6UG,Z?QF?\`!9G]DL_LC?MZ?%31M"TU-/\`AC\99&^/
M/PL2WC5+*RTKQ[J>I/XS\,6ZP1QVEH/"?Q'LO%MAIFBVX4:7X,G\'%XT6[C+
M_,_BC]L+XB^*/V(?A'^P]>O-_P`*_P#A1\=_B-\9+"\:X!%Q9>*M%LT\*>%8
MX%598K;PSXP\5?&WQ5>M++):ZC<>.?#_`)%M:3^'9);K]>XFX9P'B=A>!<_P
MD8/"QQN%Q>+;FHREDN+I0Q6/PLI)MO$4<5A*."A'WE3J5\5)Z*HE^5<.<1X[
MPZQ7&>2XGF^M2PF(PV$44WRYQAJWL,#B8I^[&C5PV*EC92:O.C2IQCS-P4O"
M/A!\*?&OQT^*GPV^"O@3S-1\>_%OQQX:\!>';G4#<7BKK?BO5K?3FU_79E$E
MPVG:2MQ=>(O$NH.6:VTK3]2OYWVPN]?ZEGP/^$/@[X!?!WX7_!/X>VS6O@OX
M3^`_"_@#PXDJQB[N=-\+Z3;:5'J6IR1HAN]8UAX)=6UJ_D!N=1U:^O;^Z>6Y
MN9'/\?O_``;3?LE2^.OCI\3OVQO$VF"3PY\!]+N/A=\+[JX@)AG^+7Q!T17\
M;ZE87`8&._\`!7PJU*#1[J)QY=Q:_&&)E/F6;A/ZGOVZ?VK/#7[%7[*WQ=_:
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MDG_@B7\6/V+OV<?VE_$?[2'[7WQ>T[X=WWPU\(3:+\#M#N?`_P`3/&=SJ/C#
MQ[#J6A>,/&BR?#_P=XF@TH^%/`JZKX4L8-7DA_M-_B)?W5M#OT191^2M[>>/
M_BY\0;S4;QM:^(OQ8^+GCZ:\O&11<^(O'WQ.^)'B4R2>7%O1;C6?%OB[6Q'!
M"C!'OM02&(HFS']&T/\`P:__`+5#PPR3_M-?`"UN'AC:YME\.?$:[6WN&1#<
M0)=+8VJW,<,V^*.X^S0&:-5D,2,Q4?K..P7"/!_!.!X(SS/WD=+,,NJX>OBL
M,IQQ>8574H3SBM3E'!8R,(8JI6GAJCJT)KZI56'A+]WS1_,<%C.*N+.+\7QE
MDV1+.)X#'4ZN'H8ETY8/"4U"I3RNE/GQ>"E.>'IPCB::I5=,3'V]2*YXI_KY
M^TS_`,%6O^".O[4O[/\`\7OV>O'G[5EJ/#/Q9\#:SX1GU!?@7^T+=7/A[4[J
M);GPWXMTR";X2)"VL^#?$UKH_BS0_-81)K.C6,DGR(:_@@O+1$-WI\US8ZE'
M%)/927NG_;/[-U%(W>!KW3OM]M8:D=/O5!N;,WMI8WXMYH_M5K:W(D@C_IG_
M`.(7[]J/_HZ#X`?^$G\1_P`/^6';M7YQ_P#!1+_@DW\<_P#@G'X=^%_C+XB>
M-_!7Q-\'?$W7]>\)1^)/`6F^(=-LO"OBS2M+M]=TG0=?C\0PQNUWXMT.+Q-J
M6A26<LJ/%X.\0)=10/':-=</ASB/#OA_$5LEX9XMQ&:5<XK0JT\OQ\I23Q5"
MA)2J85K)\OBJ]>A3C"K&=6<JRH4H4X\Z:GU<?8?CS/:%'..).%L/EM'**,Z=
M3&X*,%_LM>M0]G#$0>98Z<J>'KR<J3C&$*3KUI3M%RDO['_^"-G[:TO[:W[%
MG@G7O%>L'4_C/\'Y$^#OQI>ZF635=8\2>&K"SD\.>/[S=()[H?$;P9<Z'XCU
M'5%M;73Y?&K>-=&TY630)L>6?\%HO^"E7A;]B7X%WWPL\*1>&/%O[2'QZ\+:
MYH7@SP?K^F:5XFT?PAX%U..\T#Q+\4_'WAG5$NM,U+PY$&U+0?"'AOQ!8W6E
M>/?%27=A=:;J_A;PWXWCM/Y&/^"7/_!136?^"<WQG\>^.9O#>K>//A[\2OAA
MKOAGQ;\/=.U*/2UUCQIX<LM0\0?!S7FN9S]GL_[*\7M<^$]7U>2*_GT3P-\0
M/&NKZ=HNO:Q8:5H]U\6?'/XX?%;]IOXP>-?C;\7-:NO&7Q/^)>NI?:G)865V
MUNDDAATWP_X0\':&DM]=6'A[0;%;'PYX1\.VTM[<0V5M9V[SZEJMQ=7U[\]A
M?!>E_P`1`Q^88J%./"5&O3S3!X9247BL1B:DJO\`9DH12]GA,%B*<G6<OXF%
MEA\/!R5:M6H_0XCQ:J+@7`X+#3G+BBO1J99B:LHRG]7H8>,:2Q[D[^TQ6,H2
MIJDH-VQ#Q%648.E"$O'X8_+A*1)*T5G;0R3.(Y)1!;+<6MA'-/(`=D37EY8V
M8FF*A[R\L[8$W%W!$_ZI?\$B_P#@H)IW_!/O]IE_%/CC1=/U7X+?%O2])^'_
M`,7]4A\/VVI^,_`^B6NK/J6B>.?"6H6]E-XCETWPWJUQ)>^-_!6E7+6WC'0"
MUY#I.K^+_"O@N"/^HG_@E[_P1[^''P-_8V\>>$OVH_`.C^+OBY^UMX,AL/CQ
MHFI!+B;P'X&OK<WWA?X/Z!JT&9='UCP;=7,'BGQ+XD\.W4=XOQ:M[?4=(UO4
M;'P%X#U2R_CZ_;]_8E^(7[`O[1_B;X%^-)KG7?#DD?\`PE/PB^(<MLEO:?$K
MX::E<S1Z1K;+"D5O:>)]&GBG\-^.M#2.%M*\3Z9>7-E!+X8U?PQJVL?:X+C#
MA/Q&Q/$O!51.>'A3=*A4=:,(YMA:2I_6<9E\DDZ53`XZ,)8=?O'5H0HX^"5-
M5:-+X_&\)\3<`X;A[C"$E#$3J>TK4W24WEF)KNJZ.%QJ=U4I8W"N-/$72C'$
M3K823Y_95*G^FYH.MZ-XET+1?$GAW6-*\0^'O$.E:=KF@:_H5_:ZMH>NZ)J]
MI%J&DZSHVJ6,UQ9:EI6J6%Q;WVGW]G<36MY:3PSV\LD4B,=:OXO/^"!O_!5`
M?"W7O#_["/[0.O'_`(5SXPUD67[-WCG5[LA/`GC36[MY!\&M9O;F3RH_!GC;
M5[AY_AS<RO&WAKQO?W/A#?=Z-XP\-6GA#^T)3D<@@]""""#W!!Y!'0@X([@5
M_)G&'">8<&YU6RG')U*;7M\NQBCR4\PP$G:EB81LE">O)7HJ[H5DX-M.#E_3
M_"?%&!XMR>AFF#?LYO\`<XW"2ES5<%C(Q3JX>H[MRC>\Z%5Z5J+C-6ESQBM%
M%%?+'TQ_,'/_`,&NG[,4T$T!_:C_`&D5$T4D)8:9\(LKYB%=V/\`A!USMW9Z
MCZ@D&OZ3OA_X2M/`'@/P3X#L+RZU&Q\$>$/#7@^RU"^6%+V^M/#.BV6B6UY>
M+;I';K=W4-BD]RMO&D"S.XB18PJCKJ*^BSWBWB/B:.%AGN:5<PA@W5EAHU*6
M'I*E.LJ<:LE["E2OSQI4U:5[<MUJW?P<FX8R'A^>(GDN68?+Y8J-.&(=#VMZ
ML:3DZ:E[2I->XYS::2;YM6TE;P3]IS]G7X<_M8_`OXE?L^?%:SN+KP5\3/#L
MVB7]S8F!=7T#4;>>#5?#/B[P[+=PW-I;>)_!WB:QTKQ1X=N;NTO+--7TFT6_
MLKZQ:XM)OP"'_!KQ^S&``?VHOVD20`"?[+^$8R<<G'_"#'&>N,FOZ>**TR/C
M+B?AJA6PV1YQB,!A\155>K0A3P]6G*LHQA[6,<11J\DY4X0A-PY>>-.DI7]G
M$G-^%.',_KTL3G&483'UZ%+V%*M6515(T?:3J^SYJ52FY152I.45/FY7.7+9
M2:?Y/?\`!.C_`()+_"G_`()Q>+_BCXP^'/Q;^*'Q'N_BIX<\,>&=5LOB!9^#
M+>TTJU\+ZIJVK6MUIK>%M`T:=KFYEU::&X%W)<0^5''Y<<<A+G]7V4$=#D$$
M$$@Y'0@@@Y!Y'/!Z<TZBO*S;-LQSW'U\SS;%U,;CL1[-5L144(SFJ5.%*FG&
MG&$$H4X1@DHI<L4MD>CEF5Y?DV#I9?EF%IX/!T95)4L/2Y^2#JU)59N//*<K
MRJ3E)^]\3;T/Q_\`VO?^"(?["?[7GB#6O'VH>$O$/P.^*GB"[NM3USXA?`G4
M=,\*R^)M7NGDN+G5?%W@O6='\1?#W7-5U&]DDN];\11^%M+\8:Y+-(^H^)II
MO*FB_(CQ'_P:RZO]LN)?!O[<EDNGL[BUL/%G[-\\]]##SY:W&N:)\<[:VO'R
M<,\7AK3QU<`KMB']>]%?391XD<<9'AZ>$R_B'&+"T8QA2H8NGA<RA2IQ5HTZ
M3S/#XR=*G%:1A"481C:*CRI(^;S3P]X-SBO4Q..R+"RQ%63G5K8:IBL!4J3E
M;FG4>`Q&&56<K-RG54Y2;DV^9MG\A?AC_@UEU$7UO+XV_;CMY=,5D^UZ=X0_
M9QEM-1FC()D^S:]KWQMU&ULY<X$9F\,:A&N"[QMNV#]A?V/?^"*7["_['7B'
M1_'^@>#-?^,7Q8T&XMM0T/XF_'/4=,\7:GX9U2V:&>'5/!WA72='\._#[POJ
MUG=1M/I7B.R\)R^,M*$C0VWBCRS+YOZWT4\W\2.-\\H3PN8<0XN6%J1<:N'P
ME+"9;3JQ:2E"LLNP^$=:G)*SIU7.+3<;<KDF\J\/^#LEKT\5E^186&)I-.G7
MKSQ..J4Y1=XSIO'5\3[*<7\,Z:C-:/FNDT@7W)Y)Y.>222<GDG)/4FEZT45\
M.?9'QS^W1^Q1\+_V]_@!JOP!^*&H:YX=TZ?Q/X7\:>'?&?A:/2Y/%7@SQ5X6
MOF>#6-`76[+4M),^I:!?>(O"&IK>V%PLOA[Q/K$,/DW<D%S#^)O_`!"\_LQ_
M]'1?M(?7^S/A%@@<<$^!NG;]!S7]/%%?59)QMQ5PYA)8')<ZQ.!P<ZTL0\-&
MGAZM+V\XTX3J1C7HU7"4HTX+W'%*S:2<I.7S>;<'\,Y[BHXS-\GPN.Q4:$<-
M&M5]LIJC"4IP@O9U81M&4YV;3E9I-\L8I?GC_P`$[O\`@G!\(/\`@G'X!\?>
M#/AEXE\6>/=4^)7C*U\6>*O'/CNW\/1>)[RUTC1+31?#/A2-O#.EZ/IZ>'?#
M).OZKID#VLET-5\7>(KF:X=+N&*#;_X*"?L*Z/\`\%!/A+H'P4\7_&/XD?"K
MP+IWC.Q\;^(++X<6WA>2Y\;7^B6=S#X;TSQ!-XFTG6(7T/0]1NYO$,6G06R+
M<^(+70]3FE$VAV./O.BO-?$&<RSE<0SQTZF=+$1Q2Q]2G1J5%B(0C3IU53G3
ME14J<(P5->SM3Y(."BXQ:[XY'E,,I>10P-&GE#HRPSP,'4A1="<Y3J4KQFJG
M+4E.;G[]Y.<G)OF=_P"<CX2_\&U_[*7PR^*/P[^(^J?&_P"-_P`1K+P!XT\.
M^-)?`7BW3OADOA7Q;/X8U2WUFPT/Q,NF^#K2]N?#UYJ%G:KK6G074*ZKIJW.
MF3N+:[F!_HT4L<ECDD#)Z9/.3^.<X[`C'&*?16F>\2Y[Q-6H8C/<RK9C5PM.
M=+#NI"A2C2A4ESU%"G0I4H7J247.3BY24*<7)QIQ2SR?A[)>'Z=>EDV78?+Z
M>)J1JUU04FZDX0<(.4ZDIS:C%M1CS<J;DTN:3;*XSXB^`/"7Q5\`>-_AAX\T
MB#7_``/\1_"7B+P+XRT.Y+BWUCPOXKTF[T/7=.E:-EDC%YIM]<VZS1LLL#2+
M+&P=%([.BO%A.=.<:E.<J=2G*,Z=2#<9PG&2E&<)+6,HRC&46M5**:U2/7E&
M,XRA.*E"<90G&23C*,E:49)Z.,EHT]&MS^86/_@UV_9CCCCC/[4O[2<I1%3S
M9-,^$)DD*K@O(5\"(N]\;W*HBY)(55(`_;?]AG]D.Q_8=^`6C?L\:#\5?'?Q
M9\'^%=?\2ZIX-U/XB6GAR#7O#6C>*+\:Y=^$K:?PUINDVMWHEEXCN]>UC3#=
MVC7ED->GTN.X.EV.FVMK]AT5]/G7&W%/$>$A@<[SBOF.%IUH8B%*M1PD>6O3
MA*G"JITL/3J*<:<ZD$U-+DG*#3BVG\[E'"'#60XF6,R?*,-E^)G1G0E5H.LG
M*C.4)RIN,ZLH.+G3A*W+I**:LTFOS8_X*+?\$R/@S_P4@\.?"_2OB9XK\:?#
MS7_A+XA\0:KX9\9^`8O#T^N2:/XLTNTL?$_A6\A\3Z3K.G/H^KWVC>%=:DEB
MMHKZWOO#-FEO<):W6H0W'Y7_`/$+Q^S'V_:A_:1ST'_$K^$77\?`N/?FOZ=Z
M*VRGC[B_(L#3RW*<\Q&$P-*=6=+#*CA*T*<JU1U:O(Z^'JSC&=1RFX*7*IRE
M))<SOGF7!?"N<8RIF&9Y)@\9C*L:4*F(J>VC4G&C3A2I*3I58*3A3A&$9-<W
M)&,;VBDOE']BO]D/X;_L-_L\^#OV=_A?>:OK>A^&+SQ%K.I^+/$D>EIXH\8^
M)/%6MWFMZOK_`(BDT>RT^PFO<W-KHU@L%JD=AH&C:/I,1\C3X0/!?^"B_P#P
M3?\`#?\`P4=T#X8^#/B#\<?BI\,?`WPSU_7/%R>%?AS9>$)K#Q7XNU/38]$T
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MH_MI?LB?#?\`;B_9\\9_L\?%"ZU?1M#\477AW5],\5^'(M+D\3^#O$GA;6[3
M6]'\0^''UFRU"PAOE:WN=(OEEM72_P##^KZUI,_^C:A.#]745YV$Q6)P&*P^
M-P=:>'Q>$K4L1AL13=JE&O0J0JTJD'JE*,X1>J::NFFFT^W%87#X[#5\'BZ,
M,1A<32J4,10J*\*M&K"5.I3DE9VE"35TU);Q::3/YB/^(7K]F+_HZ+]I'_P6
M?"+IT_Z$;\*^D_V1_P#@W]_99_93^/O@C]H!OB3\5?C-K?PWFN-:\%^%?B39
M>`%\*:1XW5(TT'QO/:>'_"VF7>H:UX0<SZEX7BN;G[+I/B3^S/$\"#6=!TBY
MMOWDHK['&>)7'6/PN(P6*XCQD\-BJ,Z&(I0I8.A[6C5CR5*<IT,-3J*$XWC)
M1G&\6XO1N_RV&\/^#,'B</C,-P[@*6)PM:G7H54JTW3K4FI4ZB4ZTHN4))2C
MS)I22E9M(0#@Y)).2223DGKU)/Z_C7YQ?\%//^"??@__`(*%?LXZI\.9WTCP
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M4-,N[NQN+6[E_N)_X(:?\%4S^U?X#B_9?^/_`(J:Y_:=^%N@+/X9\4Z]>&74
M?CW\--)B2V_MZ2\N6:;4OB;X'MUM++X@PW+OJ7B?2Y-/^(=O/JES<^.D\,_(
MG_!R[^Q]\--*\-?#7]M_PZO]@?$W7?'?AWX%_$>QL;*);#XB:;=>$/&&N^#O
M%6KRQSPB#Q3X+L?!=QX674C9WEWK_AB_T+2-0NHK7P5H,2_R??#_`.(/CCX3
M^/?!WQ.^&GB?4O!GQ"^'WB/3O%?@OQ9H[1+J&@Z_I<WG6MW''<1SVE[:RJ9+
M+5=)U&WN](UW2+F^T36;*^TG4+VSG_L*O@LL\9^`L'C716!S11J2PM>47+^S
MLYH*,,52C--2KY?C'&$:EVI?5ZE.;B\3AHI_RC1Q>8^$G&V*PJJRQN6R='ZQ
M04HIX_*:S4\--QLXTL?A8SE*FVH0=>G5AS0P^(;/]97)]#^8_P`:*_GN^%'_
M``6_U7Q;\+?AKXK\3?LU:9+XD\3>`/!WB'Q#+H?Q8O\`2-$DUS6O#NG:EJTF
MCZ3>^`M;O-,TM[^YN&T_3KO6=7N;*T,-M/J=_+$]U*5_+=7@;BVE5J4IY52Y
MJ525.5LQP37-"7+*S]KJKIV[V\S^G*7%&15:=.K'&U%&I"%2-\%B$U&<8R5T
*KZI2UU>JWU/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
